Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).

@article{Sakamoto2012LandiololAU,
  title={Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).},
  author={Atsuhiro Sakamoto and Masafumi Kitakaze and Shinichi Takamoto and Akiyoshi Namiki and Hiroshi Kasanuki and Saichi Hosoda},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2012},
  volume={76 5},
  pages={1097-101}
}
BACKGROUND Recent studies have suggested that esmolol is the first choice for rate control in patients with postoperative atrial fibrillation (AF) after coronary artery bypass surgery, but side-effects of esmolol such as hypotension are problematic. To overcome this problem, landiolol, an ultra-short-acting β(1)-blocker with a less negative inotropic effect than esmolol, has been developed. The aim of the present study was to investigate whether landiolol was effective for both rate control and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…